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David Min, MD, Zoran B. Popovic, MD, PHDLiterature is the art of discovering something
extraordinary about ordinary people, and saying
with ordinary words something extraordinary.
—Boris Pasternak (1)T he same can be said about scientiﬁc insights.In fact, profound scientiﬁc discoveries areoften based on systematic approaches to
the most mundane observations. Our knowledge of
physical world is very much based on observing
how ball rolls down an inclined plane made by Gali-
leo. Likewise, our knowledge about fundamental bio-
logical laws of heredity is based on observing the
color of pea ﬂowers (2). In cardiology, profound
insights in the prognosis after acute myocardial
infarction (MI) were gained by simply looking at ven-
tricular size (3). Further observations on why some
patients do, and some do not, develop mitral regurgi-
tation (MR) after MI led to an understanding of how
local left ventricular (LV) remodeling affects mitral
valve (MV) geometry by tethering of otherwise
“normal” leaﬂets. Findings from our group have
contributed to this ﬁeld, by describing that, for the
same amount of valve tethering, ischemic MR is
more severe than functional MR in dilated cardiomy-
opathy (4). Still, our observations did not explain
why, or even recognize this as a question, and the
current paper ﬁlls this void. But before we delve
into innovations of this paper, a review of the biology
behind MV function is necessary.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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disclose.MV competency is dependent on the orchestrated
function of the mitral leaﬂets, chordae tendinae,
papillary muscles, subjacent LV myocardium, and
ﬁbromuscular annulus (5). At an ultrastructural level,
there is a well-organized network of extracellular
components across the leaﬂets that contribute to its
highly precise spatial and temporal biomechanical
properties (6). This network shows adaptive capacity,
ﬁrst being expressed during embryological develop-
ment. In embryos a subset of endocardial cells tran-
sition from endothelial cells to mesenchymal cells in
response to transforming growth factor beta (TGF-b)
proteins (7,8), resulting in organized lamellar and
ﬁbrous tissue (9). This cellular array changes as we
grow and age in response to chronic mechanical
loading (10). Changes in leaﬂet distensibility are also
reversible in nonpathologic states. Wells et al. (11)
demonstrated in a pregnant bovine model that
changes in extensibility varied depending on the
state of pregnancy (early vs. late). Whether the
observed alterations to structural and material MV
properties were in response to the physiological car-
diovascular changes of pregnancy or the changes in
hormonal milieu could not be separated, but the
ﬁndings supported the postulation of an adaptable
MV structure. Thus, we know that structure and
distensibility of mitral leaﬂets change with growth,
with aging, and during pregnancy. But what about in
pathologic conditions?
A common dogma has been that MR in ischemic
heart disease and idiopathic cardiomyopathy, so called
“functional MR,” is a consequence of ventricular dis-
ease (i.e., mitral annular dilation, displaced papillary
muscles, reduced transmitral closing pressure) in the
setting of “normal” MV leaﬂets (12–15). However,
Timek et al. (16) elegantly demonstrated in an ovine
tachycardia-induced cardiomyopathy (a model for
nonischemic cardiomyopathy), that MV leaﬂets elon-
gate. In their subsequent experiment, Rausch et al. (17)
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289showed that tethering imposed by an inferior MI also
leads to mitral leaﬂet elongation, albeit to a smaller
degree. Again, this is in concordance with the prior
observations of milder MR for the same amount of
valve tethering in functional (nonischemic), versus
ischemic cardiomyopathy. Thus a central question is
the mechanism of the This topic was originally
explored by Dal-Bianco et al. (18) in an ovine model
of valve tethering by apical retraction of papillary
muscle tips, which resulted in increased mitral leaﬂet
area and thickness. The authors then demonstrated
that the mechanical stress-induced MV changes were
an active consequence of cell activation and matrix
production. By ﬂow cytometry, they found a number
of endothelial cells (CD31þ) coexpressing a-smooth
muscle actin (a-SMA) in the tethered leaﬂets (18). This
is important as a-SMA coexpression indicates reac-
tivation of embryonic development pathways. This
ability of embryonic pathway reactivation was further
conﬁrmed in vitro when MV endothelial cells treated
with TGF-b1, TGF-b2, or TGF-b3 expressed a-SMA.SEE PAGE 275The next question was whether ischemic myocar-
dial injury modulates leaﬂet response to valve teth-
ering. In the current issue of the Journal, Dal-Bianco
et al. (19) address this question by expanding on
their previous work by introducing 2 modiﬁcations of
the tethered MV model described previously. In a ﬁrst
modiﬁcation, an apical MI (used instead of posterior/
inferior MI in order not to modify mitral apparatus)
was introduced. In a second, an apical MI was intro-
duced while a surgical mesh was implanted to limit LV
remodeling. The authors show that the presence of
MI, even when LV remodeling is prevented, dramati-
cally up-regulates embryonic development pathways,neovascularization, and TGF-b and hematopoietic cell
expression, and increases valve thickness. In other
words, ischemic heart disease dramatically alters the
way MV leaﬂets react to mechanical stimulus brought
about by MV tethering.
These ﬁndings are insightful and clinically relevant;
7.6 million Americans have a history of MI and
ischemicMRdevelops in approximately 50% of patient
after myocardial injury (20,21), and the presence of MR
after MI is associated with a doubling in mortality
(22,23). Despite its clinical impact and decades of
investigation, the treatment of functional regurgita-
tion remains controversial. MV surgery does not lead
to LV reverse remodeling or survival beneﬁt (24,25).
The 2015 American Heart Association/American Col-
lege of Cardiology (26) valvular heart disease practice
guidelines reﬂect the dearth of suitable treatment
options of chronic secondary MR with Class I recom-
mendations limited to guideline-directed medical
therapy for heart failure and cardiac resynchronization
therapy to qualifying patients.
In this context, the ﬁndings of the current study by
Dal-Bianco et al. (19) should prompt further investi-
gation into the pathways of MV adaptation. Simply
put, the authors show that mitral leaﬂets are not dead
tissue. Perhaps, its biological response can be modu-
lated. Indeed better insights into how to prevent or
reverse maladaptive response of the MV may identify
new therapeutic targets in order to optimize leaﬂet
tissue characteristics and valvular function before the
development of substantial MR.
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